Neoadjuvant Chemotherapy In Stadium Ib3, Iia2 And Iib Cervical Cancer


  • I Gde Sastra GdeSastra Winata Obstetrics and Gynecology Department of Udayana University/Sanglah General Hospital Bali



, Neoadjuvant Chemotherapy, Paclitaxel, Carboplatin, stadium IB3, IIA2 and IIB cervical cancer.


Aim: This study aimed to describe Paclitaxel-Carboplatin chemotherapy as neoadjuvant chemotherapy in stage IB3, IIA2 and IIB cervical cancer.


Materials and Methods: The review was conducted by collecting journals from previous studies discussing neoadjuvant chemotherapy in cervical cancer stages IB3, IIA2, and IIB and in this case specifically discussing Paclitaxel-Carboplatin chemotherapy.


Results: Neoadjuvan chemotherapy refers to systemic therapy intended to reduce the size of the tumor before the definitive operation. Several studies have shown that neoadjuvant chemotherapy has greater advantages than surgery alone for early stage cancers (IB3, IIA2, and IIB). Paclitaxel and Carboplatin are known chemotherapeutic agents that can be used as neoadjuvant chemotherapy.


Conclusions: Neoadjuvant Chemotherapy regimen Paclitaxel Carboplatin is one of the options in performing therapy for early stage cervical cancer which can be very helpful in healing and cancer-free patient condition. Neoadjuvant chemotherapy followed by radical surgery has significant benefits that have been described in several previous studies. 


Clinical Significance: Neoadjuvant Chemotherapy regimen Paclitaxel Carboplatin may be used as therapy regimen for early stage cervical cancer with all advantage compared to only surgery. Thus, this type of regimen can be used to decrease mortality and morbidity in patient with stadium IB3, IIA2 and IIB cervical cancer.



Mori Yukiko., Nishimura Takafumi., Kitano Toshiyuki., et al. Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX. Oncology 2010;79(1–2):136–43. Doi: 10.1159/000320613.

Masood Shahla. Neoadjuvant chemotherapy in breast cancers. Women’s Health 2016;12(5):480. Doi: 10.1177/1745505716677139.

Hayes Daniel F., Schott Anne F. Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator? JNCI Monographs 2015;2015(51):36–9. Doi: 10.1093/JNCIMONOGRAPHS/LGV004.

Singh Rajkumar Bikramjit., Chander Subhash., Mohanti B.K., et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: A pilot study. Gynecologic Oncology 2013;129(1):124–8. Doi: 10.1016/J.YGYNO.2013.01.011.

Salihi Rawand., Leunen Karin., Moerman Philippe., et al. Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I–II Cervical Cancer. International Journal of Gynecologic Cancer 2017;27(6):1256–60. Doi: 10.1097/IGC.0000000000001021.

Gallego-Jara Julia., Lozano-Terol Gema., Sola-Martínez Rosa Alba., et al. A Compressive Review about Taxol®: History and Future Challenges. Molecules 2020, Vol 25, Page 5986 2020;25(24):5986. Doi: 10.3390/MOLECULES25245986.

Bocci Guido., Paolo Antonello di., Danesi Romano. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 2013;16(3):481. Doi: 10.1007/S10456-013-9334-0.

Williams Gynecology, 3e | AccessMedicine | McGraw Hill Medical. Available at: Accessed October 6, 2021.

Zhou Jin., Li Xiong., Huang Kecheng., et al. Young Cervical Cancer Patients May Be More Responsive than Older Patients to Neoadjuvant Chemotherapy Followed by Radical Surgery. PLOS ONE 2016;11(2):e0149534. Doi: 10.1371/JOURNAL.PONE.0149534.

Wiraswesty Ika., Respati Supriyadi Hari., Sulistyowati Sri., et al. The Effect of Neoadjuvant Chemotherapy on HIF-1α Expression in Cervical Uterine Cancer. Indonesian Journal of Medicine 2018;3(2):119–24. Doi: 10.26911/THEIJMED.2018.03.02.08.

Prueksaritanond Nisa., Chaisarn Parichat., Yanaranop Marut. The Efficacy of Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Radical Hysterectomy Compared to Radical Hysterectomy alone in Bulky Stage IB2-IIA Cervical Cancer. J Med Assoc Thai n.d.;95:2012.

Rydzewska Larysa., Tierney Jayne., Vale Claire L., et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. The Cochrane Database of Systematic Reviews 2012;2012(12). Doi: 10.1002/14651858.CD007406.PUB3.

Gupta Sudeep., Maheshwari Amita., Parab Pallavi., et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. Https://DoiOrg/101200/JCO2017759985 2018;36(16):1548–55. Doi: 10.1200/JCO.2017.75.9985.

Liu Fang., Jin Tao., Liu Lei., et al. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. PLOS ONE 2018;13(3):e0194733. Doi: 10.1371/JOURNAL.PONE.0194733.

Ye Qingjian., Yang Yuebo., Tang Xinran., et al. Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy (with or without Chemotherapy) in Patients with Stage IB2, IIA, or IIB Cervical Cancer: A Systematic Review and Meta-Analysis. Disease Markers 2020;2020. Doi: 10.1155/2020/7415056.

Khatimah Gistin Husnul., Muhammad Syamel. Hubungan Tipe Histopatologi dengan Respon Kemoterapi Neoadjuvant pada Kanker Serviks Stadium IB2 dan IIA2. JOURNAL OBGIN EMAS 2019;3(2):63–81. Doi: 10.25077/AOGJ.3.2.63-81.2019.

Matsuo Koji., Mandelbaum Rachel S., Machida Hiroko., et al. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. Journal of Gynecologic Oncology 2018;29(6):91. Doi: 10.3802/JGO.2018.29.E91.

WHO | Comprehensive cervical cancer control. Available at: Accessed October 6, 2021.

Vizcaino A Paloma., Moreno Victor., Bosch F Xavier., et al. INTERNATIONAL TRENDS IN THE INCIDENCE OF CERVICAL CANCER: I. ADENOCARCINOMA AND ADENOSQUAMOUS CELL CARCINOMAS n.d. Doi: 10.1002/(SICI)1097-0215(19980209)75:4.

Vinh-Hung Vincent., Bourgain Claire., Vlastos Georges., et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007 7:1 2007;7(1):1–13. Doi: 10.1186/1471-2407-7-164